Welcome to: Rimonabant Information Source (rimonabant a)

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Effective weight loss with Rimonabant
- rimonabant,
- where is rimonabant approved
- who will market rimonabant
- rimonabant structure
- buy rimonabant + links
- rimonabant a
- rimonabant accomplia
Rimonabant Pricelist
Please wait while we load the price list
Sanofi-Aventis SA says Acomplia, its new anti-obesity drug, may benefit from the sale exceed $ 3 billion per year. "I can tell you that my expectations of $ 3 billion is not too much ,"... Related Results Cheyenne, Wyo.-area doctors skeptical of 'super bill' for weight loss, smoking. Pounds-off prescription Blockbuster obesity drug aims to win $ 4BN sales for Sanofi-Aventis obesity drug to generate a splash. " (Sanofi-Aventis) Long-term benefits of rimonabant in two-year study.
Orlando, Florida, March 4 / PRNewswire / - Obesity is a major public health problem and a major security risk factor for developing cardiovascular disease, the leading cause of mortality worldwide. (1) The 2-year RIO-Europe study is one of four Phase III studies of the RIO program, which the efficacy and safety of rimonabant, the first in a new class of therapeutic agents called CB1 blockers. Related Results Cheyenne, Wyo.-area doctors skeptical of 'super bill' for weight loss, smoking. Pounds-off prescription FDA Should not Approve Diet Drug, Panel Says Pill can help overweight and smoking. (News) (Brief article) Shares in Sanofi fall after anti-obesity drug setback WHAT: Two-year data from the RIO-Europe Study: Metabolic effects of rimonabant in Overweight / Obese patients who: M. Luc Van Gaal
